Street Calls of the Week
TYLER, Texas - NanoVibronix, Inc. (NASDAQ:NAOV), a micro-cap medical technology company with a market value of $5.17 million, announced Monday that its subsidiary ENvue Medical Holdings has been granted U.S. Patent No. 12,409,105 B2 for a system that guides the insertion of medical devices such as feeding tubes using electromagnetic positioning technology. According to InvestingPro analysis, the company maintains a favorable cash position relative to its debt obligations.
The patent, titled "Insertion Device Positioning Guidance System and Method," was issued by the United States Patent and Trademark Office on September 9, 2025. According to the company’s press release statement, the technology is designed to improve real-time visualization and accuracy during medical procedures. The company generated $2.34 million in revenue over the last twelve months, though it remains unprofitable with negative earnings.
"We believe this new patent is a significant milestone for us and highlights the strength of our innovation," said Doron Besser, Chief Executive Officer of NanoVibronix.
The patent protects systems and methods that aim to reduce the risk of misplacement and associated complications when inserting medical devices, potentially helping clinicians perform procedures with greater safety.
NanoVibronix, headquartered in Tyler, Texas, focuses on two technology platforms: acoustic-based therapeutic technologies and the ENvue Navigation Platform. The ENvue platform is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes. It has received FDA 510(k) clearance for adult use.
The medical technology company specializes in both non-invasive and minimally invasive solutions for clinical and home care settings. Its product portfolio includes PainShield and UroShield, which utilize surface acoustic wave technology.
NanoVibronix trades on the Nasdaq under the ticker NAOV. The stock has shown significant volatility, gaining over 21% in the past week despite a challenging year. InvestingPro subscribers can access 8 additional key insights about NAOV’s financial health and market performance.
In other recent news, NanoVibronix, Inc. announced that its subsidiary, ENvue Medical Holdings, has been granted a U.S. patent for technology that integrates electromagnetic navigation data with real-time medical imaging. This innovation is aimed at aiding clinicians in visualizing the placement of medical devices such as feeding tubes and catheters. Furthermore, NanoVibronix has secured $8 million in funding through a definitive agreement with an institutional investor, involving the sale of Series H Convertible Preferred Stock. The company also announced a 1-for-10 reverse stock split, effective August 11, 2025, as approved by its shareholders. This decision was part of a broader proposal that authorized a potential reverse stock split at a ratio ranging from 1-for-2 to 1-for-50. Meanwhile, NanoVibronix had to adjourn a special meeting due to a lack of quorum, with plans to reconvene the meeting on July 17, 2025. Shareholders have been advised on the new deadlines for submitting proxies for the upcoming meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.